The 20 Best Lung Cancer Doctors in The United States

Joe Chang is a Radiation Oncologist in Houston, Texas. Dr. Chang is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC).

Percy Lee is a Radiation Oncologist in Newport Beach, California. Dr. Lee is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Liver Embolization.

Suresh Ramalingam is an Oncologist in Atlanta, Georgia. Dr. Ramalingam has been practicing medicine for over 34 years and is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Raymond Osarogiagbon is a Hematologist Oncology specialist and a Hematologist in Southaven,, Mississippi. Dr. Osarogiagbon is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Nodules, Lung Adenocarcinoma, and Endoscopy.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Charu Aggarwal is an Oncologist in Philadelphia, Pennsylvania. Dr. Aggarwal is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Aggarwal is currently accepting new patients.

Balazs Halmos, MD received his medical degree summa cum laude from Semmelweis University in Budapest, Hungary. He completed an internal medicine residency program at St. Dr. Halmos is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

I am a part of the thoracic oncology program. I work with patients who have cancers of the lung, which includes non-small cell lung cancer, small cell lung cancer, and mesothelioma. My focus is on clinical care, clinical trials, and developing new therapies for these diseases. When I first meet with a patient, I want them to understand what their diagnosis is, because there are actually multiple diagnoses of lung cancer and each are treated differently. Then I discuss with a patient whether they are a candidate for therapies such as molecular therapy or immunotherapy, and make sure they have a clear understanding of the treatment plan. There are some very promising new therapies for these diseases and we are fortunate to have those available to patients here at Duke. That’s one of the unique things we offer as an academic medical center. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Young Chae is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Chae has been practicing medicine for over 24 years and is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy.

Daniel Costa is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Costa is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Liza C. Villaruz, MD, is board-certified in medical oncology and hematology at UPMC Hillman Cancer Center, and she specializes in lung cancer and thoracic malignancies. Dr. Villaruz is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

Josephine (Joy) Feliciano, M.D., is an assistant professor of oncology at The Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Kimmel Cancer Center. She serves as medical director of the Thoracic Oncology Program at Johns Hopkins Bayview Medical Center, as well as co-director of the outpatient oncology clinic at Johns Hopkins Bayview. Dr. Feliciano completed both undergraduate and postgraduate medical training at Georgetown University, as well as residency training, where she was selected as chief resident. She spent three years at Northwestern completing clinical training in hematology and oncology, then joined the faculty at University of Maryland Greenberg Cancer Center. At the University of Maryland, Feliciano focused on lung cancer screening and health disparities research for patients with lung cancer. While there, she also earned a certificate degree in the Epidemiology and Human Genetics Program for Clinical Investigation. Dr. Feliciano is also a member of the Miller Coulson Academy of Clinical Excellence. She also serves as the inaugural Medical Director of the Sidney Kimmel Cancer Diagnostic and Treatment Planning Center. Dr. Feliciano is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

I am a medical oncologist and researcher who specializes in treating patients with lung cancer and head and neck cancer. I’ve been at Duke for eight years. I first realized I wanted to become a doctor in graduate school, because it gave me the opportunity to practically apply scientific evidence to help others. What I love most about my job is working with our research and clinical staff to come up with new and hopeful therapies for patients. When a patient comes to see me, I look at their past and current medical history, review their lab tests, and then work with a team to figure out which treatment would work best for them. If a patient comes from far away, we try to make sure we can fit in visits with all the relevant specialists before they leave. Outside of work, I enjoy exercising with friends and spending time with my children at their various activities. Dr. Ready is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Conor Steuer is an Oncologist in Atlanta, Georgia. Dr. Steuer has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Gastrostomy.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Squamous Cell Lung Carcinoma, and Non-Small Cell Lung Cancer (NSCLC).

Gregory Masters is an Internal Medicine specialist and an Oncologist in Middletown, Delaware. Dr. Masters is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Endoscopy.

Nagashree Seetharamu, MD, MBBS, is an Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Board certified in Internal Medicine, Hematology, Medical Oncology and Hospice/Palliative medicine, she specializes in cancers of the head and neck and thoracic malignancies (lung cancer, mesothelioma, thymic tumors). She maintains an active clinical practice at the Monter Cancer Center where she focuses on providing compassionate, personalized, evidence-based multidisciplinary care. Dr. Seetharamu has established her reputation at the national level through her active involvement, and leadership within influential oncology organizations that steer the direction of clinical cancer care and research across the United States, and globally. She is a full member of both the Cancer Prevention Committee and Respiratory Committee of Alliance for Clinical Trials in Oncology. This is a national, NCI-sponsored, cooperative group that develops, fund and conducts clinical trials at many academic and community oncology centers across the country. In her position on these committees, she collaborates with clinical research experts across the country to establish standards-of-care, oversees the conduct of existing clinical trials, develops innovative and impactful hypotheses, and formulate future clinical trials. Dr. Seetharamu is the institutional principal investigator on over 10 clinical trials, has co-authored over 50 publications and book chapters and is a sought after speaker at various regional, national and international events related to Head and Neck and Thoracic cancer. Dr. Seetharamu is also Associate Program Director of the Medical Oncology and Hematology Fellowship Program for the Northwell Health Cancer Institute. In this role, she provides hands-on involvement in the recruitment, education and mentorship of future generations of physicians. Dr. Seetharamu trained in internal medicine at Long Island Jewish Medical Center and in hematology/oncology at New York University Medical Center. Dr. Seetharamu is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Dr. Raymond Mak is an Associate Professor of Radiation Oncology at Harvard Medical School and Director of Clinical Innovation, Thoracic Radiation Oncology Disease Site Leader, and Director of Patient Safety/Quality in the Department of Radiation Oncology at Brigham and Women’s Hospital/Dana-Farber Cancer Institute.Dr. Mak received his undergraduate degree from Cornell University and medical degree from Harvard Medical School, trained at the Harvard Radiation Oncology Residency Program, and is board certified in Radiation Oncology.Dr. Mak has over 10 years of experience in radiation treatment of thoracic malignancies including lung cancer, mesothelioma, and thymomas, and in the clinical application of advanced radiation therapy techniques including stereotactic body radiation therapy.  He has applied stereotactic body radiation therapy for novel indications including the treatment of cardiac arrhythmias. He led the implementation of MR-guided radiation therapy and adaptive radiation therapy program at BWH/DFCI in 2019 and has expertise in these innovative new treatment approaches. His research interests focus on developing genomic and imaging biomarkers to predict radiation therapy response and toxicity for lung cancer patients, and applying artificial intelligence techniques to automate radiation therapy planning and improve patient care. He has expertise in developing new methods to reduce the risk of cardiac and pulmonary toxicity for patients receiving radiation therapy. Dr. Mak is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

I have the privilege of treating patients with both benign and malignant conditions of the chest. While in college at Georgia Tech, I envisioned a career as a biomedical engineer. What I quickly learned, however, was that I was more interested in patients and their medical problems than developing the technology to care for them. During my medical education and training, I learned not only how to become a surgeon, but also learned the value of teamwork and family in caring for patients. As a thoracic surgeon, one of the best and most important aspects of my job is being able to establish a relationship with my patients and their families, working together to help them through their illness. Dr. Tong is rated as an Elite provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Lung Nodules, Pleuropulmonary Blastoma, Vagotomy, and Advanced Bronchoscopy.

David Waterhouse is a Hematologist Oncology specialist and an Oncologist in Cincinnati, Ohio. Dr. Waterhouse is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Colorectal Cancer. Dr. Waterhouse is currently accepting new patients.